Research
Hormonal
Semaglutide (2.4 mg weekly) produces greater weight loss than Liraglutide (3.0 mg daily) in patients with obesity or overweight with comorbidities.
Semaglutide (2.4 mg weekly) is a highly effective treatment for obesity, producing greater weight loss than Liraglutide. It is administered once weekly via injection, with a dose titration from 0.25 mg to 2.4 mg. Due to high demand, supply shortages may occur, so availability should be checked with a healthcare provider.
StrongSupportsHIGH confidence
Zudem kann Semaglutid das Körpergewicht noch stärker reduzieren als Liraglutid.
Why this rating
Based on the STEP 1 Phase III trial cited.
Source
Neue Behandlungsmöglichkeiten der Adipositas
Ellen Heitlinger et al. · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →